Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases

Area of Science:

• Biomedical Science
• Genetics
• Pharmacology

Background:

• The global aging population is increasing, leading to a rise in age-related diseases (ARDs).
• Current treatments for ARDs often target symptoms rather than underlying molecular causes.
• Antisense oligonucleotides (ASOs) present a novel approach for sequence-specific gene expression regulation.

Purpose of the Study:

• To review the connection between hallmarks of aging and major ARDs.
• To highlight recent advancements in ASO-based therapeutics for ARDs.
• To discuss the potential of ASOs in addressing the molecular etiology of aging-related conditions.

Main Methods:

• Literature review of preclinical and clinical studies on ASOs for ARDs.
• Analysis of gene dysregulation in aging processes and associated diseases.
• Examination of emerging ASO delivery strategies.

Main Results:

• ASOs can target key pathological mechanisms in ARDs, including protein aggregation, inflammation, metabolic dysfunction, and fibrosis.
• Studies show ASOs' potential for direct intervention in disease etiology by modulating gene expression.
• Advancements in delivery systems like ligand conjugates and lipid nanoparticles are improving ASO efficacy.

Conclusions:

• ASOs represent a promising therapeutic modality for ARDs by enabling precise control over pathogenic gene expression.
• Challenges in tissue-specific delivery and long-term safety need to be addressed for widespread clinical application.
• ASOs have the potential to significantly alter the treatment landscape for age-related diseases.